Free Trial

Stryker (SYK) Stock Forecast & Price Target

Stryker logo
$378.62 -14.11 (-3.59%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$378.62 0.00 (0.00%)
As of 08/1/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
15

Based on 19 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 4 have given a hold rating, and 15 have given a buy rating for SYK.

Consensus Price Target

$429.35
13.40% Upside
According to the 19 analysts' twelve-month price targets for Stryker, the average price target is $429.35. The highest price target for SYK is $456.00, while the lowest price target for SYK is $370.00. The average price target represents a forecasted upside of 13.40% from the current price of $378.62.
Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

Sign Up

SYK Analyst Ratings Over Time

TypeCurrent Forecast
8/2/24 to 8/2/25
1 Month Ago
7/3/24 to 7/3/25
3 Months Ago
5/4/24 to 5/4/25
1 Year Ago
8/3/23 to 8/2/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
15 Buy rating(s)
15 Buy rating(s)
15 Buy rating(s)
15 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$429.35$427.30$426.53$373.11
Forecasted Upside13.40% Upside9.00% Upside12.66% Upside12.53% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Stryker Stock vs. The Competition

TypeStrykerMedical CompaniesS&P 500
Consensus Rating Score
2.79
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside13.40% Upside10,407.36% Upside14.55% Upside
News Sentiment Rating
Positive News

See Recent SYK News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/1/2025Wells Fargo & Company
3 of 5 stars
Larry Biegelsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$435.00 ➝ $445.00+17.27%
8/1/2025Needham & Company LLC
2 of 5 stars
Mike Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$442.00 ➝ $448.00+13.89%
7/14/2025BTIG Research
2 of 5 stars
 Reiterated RatingBuy ➝ Buy
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vijay Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$390.00 ➝ $415.00+5.80%
5/22/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joanne Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$443.00 ➝ $455.00+20.09%
5/5/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lee Hambright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$450.00+17.24%
5/5/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Richard Newitter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$390.00 ➝ $400.00+4.93%
5/5/2025JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Turkaly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/2/2025Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason Wittes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$405.00 ➝ $456.00+20.75%
3/4/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set Target$422.00+12.41%
2/10/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matt Miksic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$418.00 ➝ $443.00+13.18%
2/3/2025Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$450.00+17.62%
1/29/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Shagun Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$425.00 ➝ $435.00+11.57%
1/29/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robbie Marcus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$420.00 ➝ $445.00+12.68%
1/29/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Rick Wise
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$400.00 ➝ $440.00+11.41%
1/29/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kyle Rose
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$420.00 ➝ $435.00+10.15%
12/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$370.00 ➝ $445.00+13.48%
10/30/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$380.00 ➝ $420.00+17.04%
10/30/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$366.00 ➝ $370.00+2.61%
10/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$378.00 ➝ $405.00+12.73%
9/10/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$405.00+11.64%
4/11/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$365.00 ➝ $400.00+15.82%
9/5/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$310.00 ➝ $315.00+10.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:12 PM ET.


Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, August 1, 2025. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Stryker Co.:

  • The current stock price is around $387, reflecting a strong market position and investor confidence in the company's growth potential.
  • Stryker Co. has a solid earnings report, with earnings per share exceeding expectations, indicating robust financial health and operational efficiency.
  • The company has a high return on equity, showcasing effective management and the ability to generate profits from shareholders' investments.
  • With a significant portion of shares owned by institutional investors, there is a strong backing from major financial entities, which often signals stability and trust in the company's future.
  • The recent upgrades from multiple analysts, including a "buy" rating from BTIG Research, suggest positive market sentiment and potential for stock appreciation.

Stryker
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Stryker Co. for these reasons:

  • The stock has a relatively high P/E ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Recent insider selling, including a significant transaction by a director, could raise concerns about the company's future prospects and management confidence.
  • The company's dividend payout ratio is at 45.41%, which, while sustainable, may limit the funds available for reinvestment into growth opportunities.
  • Market volatility and economic uncertainties could impact Stryker Co.'s performance, especially in the medical technology sector, which is sensitive to regulatory changes.
  • Despite positive earnings growth, the company's net margin is moderate, suggesting that profit generation may not be as strong as some investors would prefer.

SYK Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $429.35, with a high forecast of $456.00 and a low forecast of $370.00.

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SYK shares.

According to analysts, Stryker's stock has a predicted upside of 13.40% based on their 12-month stock forecasts.

Stryker has been rated by research analysts at BTIG Research, Citigroup, Evercore ISI, JMP Securities, Needham & Company LLC, Sanford C. Bernstein, Truist Financial, and Wells Fargo & Company in the past 90 days.

Analysts like Stryker less than other "medical" companies. The consensus rating score for Stryker is 2.79 while the average consensus rating score for "medical" companies is 2.81. Learn more on how SYK compares to other companies.


This page (NYSE:SYK) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners